Organon and Entelos extend research agreement
Organon, the human healthcare business unit of Akzo Nobel and Entelos Inc. announced a two-year extension of their ongoing rheumatoid arthritis (RA) collaboration. Financial terms were not disclosed.
"We are very pleased to continue our partnership with Organon," stated James Karis, president and CEO of Entelos. "Organon was one of the first companies to recognize the potential impact of Entelos' biosimulation capability and therapeutic expertise. We believe that our ability to consistently deliver value to our customers improves their prospects of developing drugs which directly benefit patients suffering from serious complex diseases such as RA."
"The collaboration with Entelos has generated candidate targets and biomarkers which will be pursued under the extension of our collaboration", said David Nicholson, executive vice president, Research & Development at Organon. "We continue to seek partnerships that move us to the forefront of RA research and development and look forward to the future benefits of Entelos' in silico approach in target and biomarker validation."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
